Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs

- December 7th, 2018

Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day. As quoted in the press release: “The important clinical and preclinical updates we shared today further establish Abeona’s pathway to bring long-term value … Continued

Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day.

As quoted in the press release:

“The important clinical and preclinical updates we shared today further establish Abeona’s pathway to bring long-term value to our shareholders and hope to our patients,” said João Siffert, M.D., interim Chief Executive Officer, Chief Medical Officer and Head of R&D. “We are very pleased to share next steps for our lead programs and to unveil the potential of the novel AIMTMAAV vector platform that could be a catalyst for the next generation of gene therapy.”

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply